Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose IVIg desensitization before haploidentical allogeneic HSCT in patients with strong donor-specific antibodies
ChiCTR2400087788Phase 2Not yet recruiting
- Sponsor
- Peking University First Hospital
- Start
- Aug 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of immune globulin in donor-specific antibody sensitization, sponsored by Peking University First Hospital. Primary endpoint: Primary graft failure. Planned start Aug 2024; status: not yet recruiting.
02
Drugs
immune globulin
03
Conditions
donor-specific antibody sensitization
Beyond the preview
Go deeper on ChiCTR2400087788.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400087788.